42 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
E2f1tm1Meg/E2f1tm1Meg E2f2tm1Zubi/E2f2tm1Zubi E2f3tm2.1Gle/E2f3tm2.1Gle involves: 129 * FVB/N * NIH Black Swiss	decreased cell proliferation	J:138289
	perinatal lethality	J:138289
E2f1tm1Meg/E2f1tm1Meg E2f2tm1Zubi/E2f2tm1Zubi E2f3tm3.1Gle/E2f3tm3.1Gle involves: 129 * FVB/N * NIH Black Swiss	decreased body weight	J:138289
	decreased cell proliferation	J:138289
	normal mortality/aging	J:138289
E2f1tm1Meg/E2f1tm1Meg E2f3tm1.1Gle/E2f3tm1.1Gle Rbl1tm1Htr/Rbl1tm1Htr Tg(Pax6-cre,GFP)2Pgr/? involves: 129 * C57BL/6 * FVB/N * NMRI	normal vision/eye phenotype	J:124204
E2f1tm1Meg/E2f1tm1Meg E2f3tm2.1Gle/E2f3tm2.1Gle involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N * NIH Black Swiss	abnormal adrenal cortex morphology	J:138289
	abnormal brain size	J:138289
	abnormal corpus luteum morphology	J:138289
	abnormal epiphyseal plate morphology	J:138289
	abnormal lung epithelium morphology	J:138289
	normal adipose tissue phenotype	J:138289
	normal behavior/neurological phenotype	J:138289
	decreased body size	J:138289
	decreased body weight	J:138289
	decreased cell proliferation	J:138289
	decreased circulating growth hormone level	J:138289
	decreased circulating insulin-like growth factor I level	J:138289
	decreased circulating leptin level	J:138289
	decreased circulating triglyceride level	J:138289
	decreased survivor rate	J:138289
	decreased white adipose tissue amount	J:138289
	normal digestive/alimentary phenotype	J:138289
	female infertility	J:138289
	male infertility	J:138289
	ovary hypoplasia	J:138289
	premature death	J:138289
	testis hypoplasia	J:138289
E2f1tm1Meg/E2f1tm1Meg E2f3tm3.1Gle/E2f3tm3.1Gle involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N * NIH Black Swiss	decreased body weight	J:138289
E2f1tm1Meg/E2f1tm1Meg E2f3tm4Gle/E2f3tm4Gle involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N * NIH Black Swiss	no abnormal phenotype detected	J:138289
E2f1tm1Meg/E2f1tm1Meg E2f3tm5(E2f1)Gle/E2f3tm5(E2f1)Gle involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N * NIH Black Swiss	no abnormal phenotype detected	J:138289
E2f1tm1Njd/E2f1+ E2f3tm1Lees/E2f3tm1Lees involves: 129S2/SvPas	lethality throughout fetal growth and development, complete penetrance	J:75765
E2f1tm1Njd/E2f1tm1Njd E2f3tm1Lees/E2f3+ involves: 129S2/SvPas	slow postnatal weight gain	J:75765
	testicular atrophy	J:75765
E2f1tm1Njd/E2f1tm1Njd E2f3tm1Lees/E2f3tm1Lees involves: 129S2/SvPas	embryonic lethality during organogenesis, complete penetrance	J:75765
E2f1tm1Njd/E2f1tm1Njd E2f3tm2Lees/E2f3tm2Lees involves: 129S2/SvPas * 129S4/SvJae * C57BL/6	abnormal cartilage morphology	J:147270
	abnormal cell cycle	J:147270
	abnormal chondrocyte morphology	J:147270
	abnormal long bone epiphyseal plate morphology	J:147270
	decreased body weight	J:147270
	decreased cell proliferation	J:147270
	neonatal lethality, incomplete penetrance	J:147270
E2f1tm1Njd/E2f1tm1Njd E2f3tm3Lees/E2f3tm3Lees involves: 129S2/SvPas * 129S4/SvJae * C57BL/6	no abnormal phenotype detected	J:147270
E2f2tm1Zubi/E2f2tm1Zubi E2f3tm2.1Gle/E2f3tm2.1Gle involves: 129S1/Sv * 129S6/SvEvTac * FVB/N * NIH Black Swiss	no abnormal phenotype detected	J:138289
E2f2tm1Zubi/E2f2tm1Zubi E2f3tm3.1Gle/E2f3tm3.1Gle involves: 129S1/Sv * 129S6/SvEvTac * FVB/N * NIH Black Swiss	no abnormal phenotype detected	J:138289
E2f3tm1.1Gle/E2f3tm1.1Gle Rbl1tm1Htr/Rbl1tm1Htr Tg(Pax6-cre,GFP)2Pgr/? involves: 129 * C57BL/6 * FVB/N * NMRI	abnormal amacrine cell morphology	J:124204
	abnormal eye development	J:124204
	abnormal retina bipolar cell morphology	J:124204
	decreased retina ganglion cell number	J:124204
	decreased retina rod cell number	J:124204
E2f3tm2.1Gle/E2f3tm2.1Gle E2f7tm1.1Gle/E2f7tm1.1Gle E2f8tm1.1Gle/E2f8tm1.1Gle involves: 129S6/SvEvTac	normal embryo phenotype	J:183999
E2f3tm2Lees/E2f3tm2Lees either: 129S/Sv-E2f3tm2Lees or (involves: 129S4/SvJae * C57BL/6)	abnormal cell cycle	J:147270
	abnormal cell physiology	J:147270
E2f3tm3Lees/E2f3tm3Lees either: 129S/Sv-E2f3tm3Lees or (involves: 129S4/SvJae * C57BL/6)	no abnormal phenotype detected	J:147270